1. Introduction
The World Health Organization (WHO) listed vaccine hesitancy as one of the top 10 threats to global health in 2019. Vaccine hesitancy is defined as “the reluctance or refusal to vaccinate despite the availability of vaccines [1]”. The reasons for vaccine hesitancy vary and are multifaceted, ranging from behavioral, social, and political factors. Caregivers, vaccine recipients, and frontline health workers (FLWs) must work together to increase the uptake of vaccinations to protect themselves and, in turn, protect their communities. Considering the significance of vaccine hesitancy, this paper aims to acquire insights from previous literature to determine what works to increase vaccine uptake and how we can apply this knowledge in a new conceptual model to increase the uptake of the COVID-19 vaccine. The role of frontline health workers and the importance of interpersonal communication and counseling will also be explored.
If and when the main causal factor to low vaccine uptake is access and availability, domestic and international partners must focus on supply chain issues. However, if the issue is hesitancy regardless of access, one must examine the demand-related factors contributing to low vaccine uptake. The global situation around the COVID-19 vaccine provides a perfect example. In the US, vaccine hesitancy is driven by a lack of demand linked to personal beliefs, stereotypes, and socio-cultural factors [2]. Yet, in much of the Global South, low vaccination rates are fueled by the lack of access to adequate doses of the vaccine to protect entire populations. For example, when COVID-19 vaccines were in development, high-income countries began making deals with pharmaceutical companies for pre-order [3]. Over 80% of the COVID-19 vaccine developed by Pfizer was claimed by the United States, United Kingdom, European Union, and Japan. Even if the vaccine was made available to countries in the Global South (such as Latin America, India, Southeast Asia, and South Africa), there are still costs associated with maintenance, storage, transportation, and distribution [3,4].
1.1. Childhood Vaccine Hesitancy
Immunizations are credited with saving the lives of millions of children each year [5]. However, since the introduction of the smallpox vaccine in the 1800s, immunization has also faced controversy and opposition [5,6]. One of the most well-known controversies was the fraudulent and debunked study published in 1998 by Wakefield and colleagues that falsely linked the Measles, Mumps, and Rubella vaccine to autism and helped fuel vaccine hesitancy—and the anti-vaccine movement—among caregivers [7,8]. To this day, although the national coverage of recommended vaccines for children remains steady, a sizeable number of caregivers continue to delay or refuse some or all vaccinations for their children. Consequently, vaccine-preventable disease outbreaks still appear in many parts of the world [7]. In many countries, even when policies, financing, and resources are in place and services are available, a large number of children still fail to complete immunization schedules. In 2020, global vaccination coverage dropped to 83% from 86% in 2019 [9]. It is estimated that 23 million children below one year old were un- or under-vaccinated from basic vaccines [9]. Childhood vaccine hesitancy is a significant barrier towards eliminating vaccine-preventable diseases among young children around the globe. It is clear that as countries shift their focus towards monitoring the COVID-19 pandemic and vaccination programs, that will also impact efforts to address childhood vaccinations.
1.2. COVID-19 Vaccine Hesitancy
Currently, the focus of vaccinations has shifted towards COVID-19 vaccination efforts. As of November 2021, the COVID-19 pandemic has seen 248 million cases with over 5 million deaths [10]. In December 2020, based on concerted global efforts, scientists successfully developed vaccines to help control the spread of COVID-19. Unfortunately, vaccine hesitancy has proven to be a major hindrance to COVID-19 vaccination uptake.
A recent systematic review of COVID-19 related to vaccine hesitancy globally found wide variation in vaccine hesitancy between countries, with the overall acceptance rate below 70% [11]. This systematic review also included results from eight separate studies with health care providers and reported vaccine acceptance rates among health care workers ranging from 28% in the Democratic Republic of the Congo to 78% in Israel. The review concludes that addressing the scope of COVID-19 vaccine hesitancy in various countries requires building trust in the vaccination efforts. Additionally, a study by Arce et al. (2021) examined COVID-19 vaccination acceptance among low- and middle-income countries (LMICs) in Latin America, Asia, Africa, and Russia (upper-middle class), and the United States (US) [12]. They surveyed individuals in 10 LMICs (n = 20,176) and compared responses against Russian and US respondents (n = 24,084), identified as two countries leading vaccine research and development. Findings showed that the average COVID-19 vaccine acceptance was higher in LMICs (80% acceptance) compared to Russia (30% acceptance) and the US (65% acceptance). Their findings further revealed various reasons for vaccine hesitancy and most notably included side effect concerns (40.8% in all LMICs, 36.8% in Russia, and 79.3% in the US). Other notable reasons included vaccine effectiveness doubts (29.6% in Russia and 46.8% in the US) and lack of concern related to COVID-19 infection (39.3% in the US). Vaccine hesitancy towards the COVID-19 vaccine is a significant threat to controlling COVID-19 and its various strains globally. Therefore, vaccinations are critical in the road to recovery from the COVID-19 pandemic.
CC BY 4.0. "What Determines Vaccine Hesitancy: Recommendations from Childhood Vaccine Hesitancy to Address COVID-19 Vaccine Hesitancy" by Rodrigues F, Block S, Sood S, Vaccines (2022). https://doi.org/10.3390/vaccines10010080. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Peer-reviewed and open access; full text from PubMed Central (PMC8780267). Headings and layout adapted for reading; figures and tables are in the original.